Oxymatrine Ameliorates Lupus Nephritis by Targeting the YY1-Mediated IL-6/STAT3 Axis
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252212260 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Haoxing Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory of Drug Metabolism Research and Evaluation, School of Pharmaceutical S…. Hauptthemen laut MEDLINE: Lupus Nephritis, YY1 Transcription Factor, STAT3 Transcription Factor, Interleukin-6. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Major Scientific and Technological Projects of Guangdong Province, Science and Technology Innovation Project of Guangdong Provincial Drug Administration, Major Scientific and Technological Projects of Guangdong Province.
Abstract (Originalsprache)
Lupus nephritis (LN) is a severe form of systemic lupus erythematosus (SLE), characterized by inflammation in the renal glomeruli and tubules. Previous research has demonstrated that dihydroartemisinin (DHA) can reduce inflammatory damage in LN mouse models. Oxymatrine, which has similar biological properties to DHA, may also provide therapeutic benefits. This study aims to investigate the effects of oxymatrine on LN using a murine model and examines its molecular mechanisms through an analysis of microarray datasets from LN patients. The analysis identified differentially expressed genes (DEGs) in renal tissues, regulated by the transcription factor Yin Yang 1 (YY1), which was found to be significantly upregulated in LN patient kidneys. The results indicate that oxymatrine targets the YY1/IL-6/STAT3 signaling pathway. In cell models simulating renal inflammation, oxymatrine reduced YY1 expression and inhibited the secretion of inflammatory factors (IFs), thereby diminishing inflammation. YY1 is crucial in modulating IFs’ secretion and contributing to LN pathogenesis. Additionally, oxymatrine’s interaction with YY1, leading to its downregulation, appears to be a key mechanism in alleviating LN symptoms. These findings support oxymatrine as a promising therapeutic agent for LN, offering new avenues for treating this autoimmune kidney disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory of Drug Metabolism Research and Evaluation, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou 510515, China.
- Innovation Center for Medical Basic Research on Inflammation and Immune Related Diseases, Ministry of Education, Southern Medical University, Guangzhou 510515, China.
ORCID-Profile: Shuwen Liu
Förderung
- the Major Scientific and Technological Projects of Guangdong Province
- Science and Technology Innovation Project of Guangdong Provincial Drug Administration
- Major Scientific and Technological Projects of Guangdong Province
Zitieren
APA
Yuan, H., Peng, Z., Li, H., Rao, Y., Lu, K., Yang, C., Cheng, C., & Liu, S. (2024). Oxymatrine Ameliorates Lupus Nephritis by Targeting the YY1-Mediated IL-6/STAT3 Axis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212260
Vancouver
Yuan H, Peng Z, Li H, Rao Y, Lu K, Yang C, et al. Oxymatrine Ameliorates Lupus Nephritis by Targeting the YY1-Mediated IL-6/STAT3 Axis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212260
BibTeX
@article{Yuan2024,
author = {Yuan, Haoxing and Peng, Zheng and Li, Honglian and Rao, Yuzhen and Lu, Kunyu and Yang, Chan and Cheng, Chen and Liu, Shuwen},
title = {Oxymatrine Ameliorates Lupus Nephritis by Targeting the YY1-Mediated IL-6/STAT3 Axis},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252212260}
}
EUVIMED